48.94 USD
-0.5 (-1.01%)
48.94 USD
0 (0%)
Taking everything into account, SUPN scores 5 out of 10 in our fundamental rating. SUPN was compared to 190 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of SUPN get a neutral evaluation. Nothing too spectacular is happening here. SUPN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year SUPN was profitable.
- SUPN had a positive operating cash flow in the past year.
- Each year in the past 5 years SUPN has been profitable.
- Each year in the past 5 years SUPN had a positive operating cash flow.
1.2 Ratios
- With a decent Return On Assets value of -1.35%, SUPN is doing good in the industry, outperforming 75.26% of the companies in the same industry.
- With a decent Return On Equity value of -1.82%, SUPN is doing good in the industry, outperforming 77.37% of the companies in the same industry.
- The Return On Invested Capital of SUPN (2.34%) is better than 79.47% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for SUPN is significantly below the industry average of 12.83%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| ROIC | 2.34% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
1.3 Margins
- SUPN's Profit Margin has declined in the last couple of years.
- The Operating Margin of SUPN (6.08%) is better than 79.47% of its industry peers.
- SUPN's Operating Margin has declined in the last couple of years.
- Looking at the Gross Margin, with a value of 89.91%, SUPN belongs to the top of the industry, outperforming 92.11% of the companies in the same industry.
- SUPN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.08% | ||
| PM (TTM) | N/A | ||
| GM | 89.91% |
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SUPN is destroying value.
- Compared to 1 year ago, SUPN has more shares outstanding
- SUPN has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- SUPN has an Altman-Z score of 5.86. This indicates that SUPN is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of SUPN (5.86) is better than 76.84% of its industry peers.
- SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.86 |
ROIC/WACC0.25
WACC9.38%
2.3 Liquidity
- A Current Ratio of 1.80 indicates that SUPN should not have too much problems paying its short term obligations.
- SUPN has a Current ratio of 1.80. This is in the lower half of the industry: SUPN underperforms 65.79% of its industry peers.
- SUPN has a Quick Ratio of 1.56. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.56, SUPN is not doing good in the industry: 61.05% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.56 |
3. Growth
3.1 Past
- SUPN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.32%.
- SUPN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.93% yearly.
- The Revenue has been growing slightly by 4.54% in the past year.
- The Revenue has been growing by 11.00% on average over the past years. This is quite good.
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
3.2 Future
- SUPN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.52% yearly.
- The Revenue is expected to grow by 14.93% on average over the next years. This is quite good.
EPS Next Y-5.26%
EPS Next 2Y20.17%
EPS Next 3Y17.74%
EPS Next 5Y19.52%
Revenue Next Year9.16%
Revenue Next 2Y16.26%
Revenue Next 3Y16.13%
Revenue Next 5Y14.93%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- SUPN is valuated correctly with a Price/Earnings ratio of 15.79.
- Based on the Price/Earnings ratio, SUPN is valued cheaply inside the industry as 85.79% of the companies are valued more expensively.
- SUPN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.60.
- The Price/Forward Earnings ratio is 11.49, which indicates a very decent valuation of SUPN.
- Based on the Price/Forward Earnings ratio, SUPN is valued cheaply inside the industry as 86.32% of the companies are valued more expensively.
- SUPN is valuated cheaply when we compare the Price/Forward Earnings ratio to 25.83, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.79 | ||
| Fwd PE | 11.49 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SUPN indicates a somewhat cheap valuation: SUPN is cheaper than 80.00% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, SUPN is valued a bit cheaper than the industry average as 78.95% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 39.66 | ||
| EV/EBITDA | 18.88 |
4.3 Compensation for Growth
- SUPN's earnings are expected to grow with 17.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)2.28
EPS Next 2Y20.17%
EPS Next 3Y17.74%
5. Dividend
5.1 Amount
- SUPN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SUPERNUS PHARMACEUTICALS INC / SUPN FAQ
Can you provide the ChartMill fundamental rating for SUPERNUS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 5 / 10 to SUPN.
What is the valuation status for SUPN stock?
ChartMill assigns a valuation rating of 6 / 10 to SUPERNUS PHARMACEUTICALS INC (SUPN). This can be considered as Fairly Valued.
What is the profitability of SUPN stock?
SUPERNUS PHARMACEUTICALS INC (SUPN) has a profitability rating of 5 / 10.
Can you provide the expected EPS growth for SUPN stock?
The Earnings per Share (EPS) of SUPERNUS PHARMACEUTICALS INC (SUPN) is expected to decline by -5.26% in the next year.